Loading
Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.
Andrés Ferreri led IELSG20, which established high-dose methotrexate plus cytarabine for primary CNS lymphoma, and IELSG32, which showed the MATRix regimen (adding rituximab and thiotepa) followed by autologous transplant or whole-brain radiotherapy produces durable remissions in most fit patients. He coordinates the International Extranodal Lymphoma Study Group and leads trials of novel agents in CNS and ocular lymphomas.
Shares International Extranodal Lymphoma Study Group and the tag lymphoma.
Shares Primary CNS lymphoma and the tag lymphoma.
Shares International Extranodal Lymphoma Study Group, Primary CNS lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Cytotoxic chemotherapy.
Shares International Extranodal Lymphoma Study Group, Primary CNS lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Cytotoxic chemotherapy.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma.
Shares Primary CNS lymphoma and the tag lymphoma.
Shares International Extranodal Lymphoma Study Group, Primary CNS lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Cytotoxic chemotherapy.